ALNY
Alnylam Pharmaceuticals, Inc.
Stock
$219.72−11.46 (−4.96%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $912M | $524M | −$8.3M | $104M | −$541M | −$642M | −$615M | −$278M | −$563M | −$383M | −$308M | −$189M | −$166M | −$69M | −$116M | −$87M | −$84M | −$72M | $65M |
| Capital expenditures | $92M | $59M | $34M | $62M | $72M | $76M | $70M | $140M | $127M | $104M | $65M | $13M | $9.0M | $4.0M | $8.3M | $1.3M | $4.7M | $4.9M | $11M |
| Free cash flow | $820M | $465M | −$43M | $42M | −$613M | −$718M | −$685M | −$419M | −$690M | −$487M | −$372M | −$202M | −$175M | −$73M | −$124M | −$88M | −$89M | −$77M | $55M |
| Stock-based compensation | $337M | $348M | $272M | $222M | $231M | $166M | $140M | $175M | $158M | $93M | $76M | $46M | $33M | $21M | $12M | $17M | $19M | $20M | $18M |
| Free cash flow margin | 17.1% | 12.5% | −1.9% | 2.3% | −59.1% | −85.0% | −139.1% | −190.5% | −920.5% | −541.6% | −789.4% | — | — | — | — | — | −89.0% | −76.7% | 56.9% |